David Hurley McKenna Jr. MD

Pathology•Minneapolis, MN

Blood Banking & Transfusion Medicine, Transplantation Immunology, Anatomic Pathology, Clinical Pathology

Professor, Lab Medicine & Pathology, University of Minnesota Medical School

Join to View Full Profile

909 Fulton StMinneapolis, MN 55455

Summary

Dr. David McKenna is a pathologist in Mpls/St Paul, MN. He received his MD from Saint Louis University, in practice 20+ years. He specializes in transfusion medicine, with a primary focus on cellular therapy. He directs the Division of Transfusion Medicine (TM), the cGMP facility and Cell Therapy (CT) Lab of the Univ of MN/M Health, and two fellowships (TM and CT & Regenerative Medicine).

Education & Training

University of MinnesotaFellowship, Transfusion Medicine, 2001 - 2003
University of MinnesotaResidency, Pathology-Anatomic and Clinical, 1997 - 2003
Saint Louis University School of MedicineClass of 1997

Certifications & Licensure

MN State Medical License 2003 - 2025
VT State Medical License 1997 - 1998
American Board of Pathology Anatomic Pathology & Clinical Pathology
American Board of Pathology Blood Banking/Transfusion Medicine

Clinical Trials

Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases Start of enrollment: 2007 May 01
Terminated
Phase 1
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer Start of enrollment: 2007 Jul 23
Completed
Phase 1
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant Start of enrollment: 2008 Jun 01
Terminated
Phase 1
Stem Cell Therapy in Patients With Severe Heart Failure & Undergoing Left Ventricular Assist Device Placement Start of enrollment: 2011 Nov 10
Completed
Phase 1, Phase 2
Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML) Start of enrollment: 2010 Jul 01
Terminated
Phase 2
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies Start of enrollment: 2014 Jan 01
Withdrawn
Phase 1, Phase 2
Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation Start of enrollment: 2013 Nov 08
Completed
Phase 1
Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome Start of enrollment: 2013 Jul 01
Completed
Phase 1
Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START) Start of enrollment: 2014 Mar 15
Completed
Phase 2
Treg Cells for AGVHD in Non-myeloablative UCB Transplant Start of enrollment: 2016 Jun 01
Withdrawn
Phase 2
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies Start of enrollment: 2017 Feb 16
Terminated
Phase 2
Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome Start of enrollment: 2019 Nov 26
COMPLETED
PHASE2
Join now to see all

Publications & Presentations

PubMed

The need for an organoid manufacturing, preservation, and distribution center.
Anthony Atala, John C Bischof, Christopher S Chen, John P Fisher, David L Hermanson
Stem Cells Translational Medicine. 2025-06-25
Clinical manufacture of CRISPR/Cas9-based cytokine-induced SH2 protein knock-out tumor-infiltrating lymphocytes for gastrointestinal cancers.
Matthew J Johnson, Darin Sumstad, Timothy D Folsom, Nicholas J Slipek, Anthony P DeFeo
Cytotherapy. 2025-06-21
Acute respiratory distress vs healthy lung environments differently affect mesenchymal stromal cell extracellular vesicle miRNAs.
Sara Rolandsson Enes, Irakli Dzneladze, Thomas H Hampton, Samuel L Neff, Lori Asarian
Cytotherapy. 2025-05-01

Abstracts/Posters

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multip...
David H. McKenna, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Uni...
David H. McKenna, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

Groundbreaking U of M Medical School Muscle Regeneration Research Receives Nearly $1 Million GrantSeptember 3rd, 2019

External Links

UMN profile https://med.umn.edu/bio/david-mckenna